文献速递肝病消化道肿瘤与早癌

靶向肝脏成纤维细胞生长因子受体4的双面性

Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
PubMed 文献 · J Hepatol · 2021-08-05

本文综述了FGFR4及其配体FGF19在肝脏疾病中的双重作用。FGFR4抑制剂用于FGF19超生理水平晚期肝细胞癌患者的临床试验正在进行;而FGF19类似物激活FGFR4-KLOTHOβ则可能治疗胆汁淤积性肝病和非酒精性脂肪性肝炎,预防代谢性肝细胞癌。强调需仔细分层患者并个体化治疗策略。

要点

  • FGFR4抑制剂是FGF19超生理水平晚期肝细胞癌的潜在治疗选择。
  • FGF19类似物激活FGFR4-KLOTHOβ可能治疗胆汁淤积性肝病和NASH。
  • 靶向FGFR4需仔细分层患者并个体化治疗策略。

核心结论

  • 靶向FGFR4在肝脏疾病中具有双向治疗潜力:抑制剂用于FGF19超生理水平的晚期肝细胞癌,激动剂用于胆汁淤积性肝病和NASH。

研究设计与样本

  • 本文为综述,概述了当前靶向FGFR4治疗肝细胞癌及其他肝病的治疗选择。

主要发现

  • FGFR4及其配体FGF19的异常激活与肝脏肿瘤发生相关。
  • FGFR4抑制剂在FGF19超生理水平患者中展现前景,多项临床试验正在晚期肝细胞癌中测试。
  • FGF19类似物激活FGFR4-KLOTHOβ是胆汁淤积性肝病和非酒精性脂肪性肝炎的新型治疗策略,可能预防代谢性肝细胞癌。

临床怎么用

  • 对晚期肝细胞癌患者应检测FGF19水平,超生理水平者可考虑FGFR4抑制剂临床试验。
  • 胆汁淤积性肝病和NASH患者可能受益于FGF19类似物激活FGFR4-KLOTHOβ的策略。
  • 靶向FGFR4治疗需基于分子分层进行个体化选择。

局限性

  • 肝细胞癌分子异质性高且分子靶点不明确,影响靶向治疗精准性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast growth factor (FGF) receptor 4 (FGFR4) and its cognate ligand, FGF19, are implicated in a range of cellular processes, including differentiation, metabolism and proliferation. Indeed, their aberrant activation has been associated with the development of hepatic tumours. Despite great advances in early diagnosis and the development of new therapies, liver cancer is still associated with a high mortality rate, owing primarily to high molecular heterogeneity and unclear molecular targeting. The development of FGFR4 inhibitors is a promising tool in patients with concomitant supraphysiological levels of FGF19 and several clinical trials are testing these treatments for patients with advanced hepatocellular carcinoma (HCC). Conversely, using FGF19 analogues to activate FGFR4-KLOTHO β represents a novel therapeutic strategy in patients presenting with cholestatic liver disorders and non-alcoholic steatohepatitis, which could potentially prevent the development of metabolic HCC. Herein, we provide an overview of the currently available therapeutic options for targeting FGFR4 in HCC and other liver diseases, highlighting the need to carefully stratify patients and personalise therapeutic strategies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gadaleta RM, Moschetta A. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver. J Hepatol. 2021. PMID: 34364916. doi:10.1016/j.jhep.2021.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。